Drug Type Small molecule drug |
Synonyms Glufanide disodium, Glutamyltryptophan, L-Glu-L-Trp + [9] |
Target- |
Mechanism Angiogenesis inhibitors, Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC16H19N3NaO5 |
InChIKeyUOKXDTZUCQYLHK-JZKFLRDJSA-N |
CAS Registry237068-57-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | AU | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 3 | CA | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 3 | BE | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 3 | US | 31 Aug 2001 | |
Colorectal Cancer | Phase 3 | US | - | |
Kaposi Sarcoma | Phase 3 | - | - | |
Kaposi Sarcoma | Phase 3 | - | - | |
Kaposi Sarcoma | Phase 3 | - | - | |
Kaposi Sarcoma | Phase 3 | - | - | |
Ovarian Cancer | Phase 3 | US | - |
Not Applicable | Gastritis, Atrophic H. pylori | 116 | kdfvdfpvdj(fbcwyfiyuc) = decrease of GM edema and hyperemia by endoscopy data, reduction of the number of inflammatory infiltration cells per 1 mm 2 of GM: eosinophilic granulocytes â 3 times, neutrophilic leukocytes â 4 times, macrophages â 1.5 times, lymphocytes â 28.2%, plasmocytes â 29.6% by histological study xajjbnylzs (kjrvnljrhi ) View more | Positive | 13 Oct 2024 | ||
Phase 2 | - | zjivvduqtj(zeviugufqw) = sldsutenbg qcuqojieff (pfkjaziuxj ) | Negative | 01 Jun 2005 | |||
Placebo | zjivvduqtj(zeviugufqw) = ccjhcybbhw qcuqojieff (pfkjaziuxj ) |